- What does the fixed combination of valsartan and sacubitrilu patients with heart failure - the results of the study PARADIGM-HF2017 | Faculty of Medicine in Hradec Králové
- A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure2015 | First Faculty of Medicine
- Sacubitril/valsartan - new dual inhibitor of neprilysin and angiotensin II receptors2016 | First Faculty of Medicine
- Monitoring the dynamics of clinical and laboratory markers of chronic heart failure during 12 months of sacubitril/valsartan treatment2021 | First Faculty of Medicine
- Blood pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II.receptor and neprilysin.Commentray on::Lancet 375,2010,1255-12662010 | First Faculty of Medicine
- Rationale and design of TRANSITION: a randomized trial of pre-discharge vs. post-discharge initiation of sacubitril/valsartan2018 | First Faculty of Medicine
- New views on pathophysiology, diagnostics and treatment of heart failure with preserved ejection fraction2016 | First Faculty of Medicine
- Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure2015 | First Faculty of Medicine
- Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)2013 | First Faculty of Medicine
- Studie PARADIGM-HF - Změna paradigmatu v léčbě chronického srdečního selhání?2015 | First Faculty of Medicine
